ArticleJournal of computer-aided molecular design2025
Disrupting tuberculosis pathogenesis by targeting DprE1 in cell wall biosynthesis: a structural dynamics perspective.
Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mycobacterium tuberculosis (Mtb), the causative agent of TB, remains a major global health challenge due to the emergence of MDR and XDR strains. Targeting DprE1, an enzyme essential in the biosynthesis of the mycobacterial cell wall, offers a promising therapeutic strategy. The current work utilized a computational pipeline for identifying potential inhibitors of DprE1 from the Diverse-lib database by virtual screening, molecular docking, molecular dynamics, free binding energy calculation, and free energy landscape analysis based on RMSD and Rg values. Three candidates were identified as promising inhibitors out of all the screened diverse-lib compounds. Their binding poses and interaction patterns were analyzed and compared with those of a known reference inhibitor. In molecular docking, three compounds showed high binding affinities, while MD simulations further showed stable protein-ligand complexes for more than 300 nsec in quadruplicate. Free binding energy calculation through MM/GBSA revealed energetically favorable interactions. From this RMSD-Rg-based free energy landscape, the stability in conformation was indicated in the complexes. Minima structures also strongly agreed with initial poses, evidenced by superimposition analysis. Comparison with the reference molecule revealed that the identified compounds exhibit comparable or higher binding energies and structural stability, suggesting their potential to inhibit DprE1. These findings warrant further experimental validation to confirm their efficacy against Mtb.
Indexed as
Identifiers
40632318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.